Saturday January 25, 2020

Medicines boss: Costly new cancer drugs not working

Just one in 20 new cancer drugs assessed for the Irish market since the beginning of 2016 were considered value for money, according to a new assessment by the NCPE

Susan Mitchell

Deputy Editor and Health Editor

15th October, 2017
Professor Michael Barry, heads up the National Centre for Pharmacoeconomics Pic:

Most new cancer drugs are not worth the money being sought by pharmaceutical companies, the head of the state’s medicines watchdog has said in a stark assessment.

Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), said the state was funding cancer drugs that cost anywhere between €50,000 and €100,000 per patient per year that “very often only prolong life by a few months – if even [that]”.


Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

He was once the garlanded saviour of Nissan. So how did Carlos Ghosn find himself a fugitive after one of the most glittering careers in the history of the car industry?

Barry J Whyte | 6 days ago

Our goal in the west should be to encourage the country’s leaders to make its economy more competitive, open and transparent

Vincent Boland | 6 days ago

Inflation figures do not measure the cost of living, and in our hyper-globalised economy it’s not always easy to count what’s real and what’s not

Aidan Regan | 6 days ago